← Back to Analyst Consensus 
AMAL Buy
Amalgamated Financial Corp.
Current Price —
Implied Upside —
Analysts 9
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 3, 2026 | Raymond James | initiate | — → Outperform | — | 54% |
| Jul 27, 2026 | Piper Sandler | maintain | Neutral → Neutral | — | 54% |
| Jul 24, 2026 | Keefe, Bruyette & Woods | maintain | Outperform → Outperform | — | 58% |
| Jun 26, 2026 | Piper Sandler | maintain | Neutral → Neutral | — | 54% |
| Apr 27, 2026 | Piper Sandler | maintain | Neutral → Neutral | — | 54% |
| Jul 29, 2024 | Keefe, Bruyette & Woods | reiterate | Outperform → Outperform | $35 | 58% |
| Jun 27, 2024 | JP Morgan | maintain | Overweight → Overweight | $32.5 | 54% |
| Apr 26, 2024 | Piper Sandler | reiterate | Overweight → Overweight | $29 | 54% |
| Apr 5, 2024 | Keefe, Bruyette & Woods | maintain | Outperform → Outperform | $30 | 58% |
| Apr 4, 2024 | JP Morgan | maintain | Overweight → Overweight | $29.5 | 54% |
| Jan 5, 2024 | JP Morgan | maintain | Overweight → Overweight | $32 | 54% |
| Dec 12, 2023 | JP Morgan | upgrade | Neutral → Overweight | $29 | 54% |
| Dec 1, 2023 | Keefe, Bruyette & Woods | maintain | Outperform → Outperform | $26 | 58% |
| Oct 31, 2023 | JP Morgan | maintain | Neutral → Neutral | $24 | 54% |
| Oct 5, 2023 | JP Morgan | maintain | Neutral → Neutral | $22 | 54% |
| Aug 2, 2023 | JP Morgan | maintain | Neutral → Neutral | $21.5 | 54% |
| Jun 29, 2023 | JP Morgan | maintain | Neutral → Neutral | $19.5 | 54% |
| May 1, 2023 | Keefe, Bruyette & Woods | maintain | — → Outperform | $24 | 58% |
| Apr 6, 2023 | Keefe, Bruyette & Woods | maintain | — → Outperform | $25 | 58% |
| Apr 6, 2023 | JP Morgan | maintain | — → Neutral | $19 | 54% |
| Jan 31, 2023 | Keefe, Bruyette & Woods | maintain | — → Outperform | $29 | 58% |
| Dec 20, 2022 | Piper Sandler | maintain | — → Overweight | $28 | 54% |
| Jul 1, 2022 | JP Morgan | maintain | — → Neutral | $24 | 54% |
| Nov 2, 2021 | Raymond James | maintain | — → Outperform | $20 | 54% |
| Nov 1, 2021 | Barclays | maintain | — → Overweight | $21 | 53% |
| Sep 23, 2021 | Piper Sandler | maintain | — → Overweight | $19 | 54% |
| Mar 23, 2021 | JP Morgan | downgrade | Overweight → Neutral | $17.5 | 54% |
Price Target Trend
May 12, 2026 Oct 26, 2026
EPS Estimates
+1q —
+1y —
0q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days